Product news

Share this article:

An FDA advisory panel voted that a long-acting, injectable form of Eli Lilly's best-selling drug, the antipsychotic olanzapine, is safe enough for use in some patients with schizophrenia. But panel members shared concerns raised by the FDA that Zyprexa LAI was associated with excessive sedation.

Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Business Briefs

The Women's Health landscape is ripe with opportunity for pharma marketers. This seven-page eBook offers product managers a guide to capitalizing on the trends, growth areas and unmet needs. Includes alternative channels to engage OB/GYNs and oncologists, and plenty of tips. Click here to access it.

Email Newsletters